MAPT and Huntington disease: Such selectivity for disease-specific pathology (i.e. mHTT vs. beta amyloid/tau aggregates) is highly desirable in designing and developing an HTT-aggregate-directed PET tracer to minimize any signal confound attributed to co-morbidity (i.e. presence of beta amyloid pathology) in HD patients.